Tower Research Capital (TRC)’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,643	Closed	-$100K	–	6575
2021 Q2	$100K	Sell	3,643 -5,923	-62%	-$116K	﹤0.01%	2430
2021 Q1	$158K	Sell	9,566 -118	-1%	-$2.69K	﹤0.01%	2206
2020 Q4	$178K	Buy	9,684 +3,570	+58%	+$63.9K	0.01%	1814
2020 Q3	$83K	Sell	6,114 -7,775	-56%	-$120K	﹤0.01%	3292
2020 Q2	$249K	Buy	13,889 +9,766	+237%	+$147K	0.01%	1611
2020 Q1	$41K	Sell	4,123 -52	-1%	-$426	﹤0.01%	1387
2019 Q4	$34K	Buy	+4,175	New	+$38.5K	﹤0.01%	1590
2019 Q3	–	Sell	-1,639	Closed	-$21K	–	4724
2019 Q2	$21K	Buy	+1,639	New	+$17.3K	﹤0.01%	2164
2019 Q1	–	Sell	-4,487	Closed	-$34K	–	4555
2018 Q4	$34K	Buy	+4,487	New	+$32.9K	﹤0.01%	1563

Tower Research Capital (TRC)'s TBIO Position: Q3 2021 in Review

Tower Research Capital (TRC) sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 3,643 shares — an estimated $100K sold.

Tower Research Capital (TRC) first reported a position in TBIO in Q4 2018 and held it in 9 quarters. The position peaked at $249K in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Tower Research Capital (TRC) reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Tower Research Capital (TRC) sold 3,643 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $100K.
Tower Research Capital (TRC) first reported a position in Translate Bio, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Tower Research Capital (TRC)'s Translate Bio, Inc. Common Stock position peaked at $249K in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2021, filed 15 Nov 2021.